TP53 and urinary bladder cancer: In order to test the potential senolytic effects of CUDC-907, we took advantage of the genetic models of senescence, EJp53, EJp21 and EJp16, in which the p53 null bladder cancer cell line, EJ, is induced to senesce by a tetracycline(tet)-regulatable expression of p53, p21 or p16, respectively [69–71].